HUTCHMED to Announce 2023 Final Results

Written by Emily J. Thompson, Senior Investment Analyst

HCM-0.84%

Source: businesswire

Updated: Jan 31 2024

0mins

Source: businesswire

HCM

$15.31+Infinity%1D

Analyst Views on HCM

Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 15.440

Low

22.00

Averages

22.00

High

22.00

Current: 15.440

Low

22.00

Averages

22.00

High

22.00

BofA

Buy

downgrade

$25 -> $22

2026-01-06

Reason

BofA

Price Target

$25 -> $22

AI Analysis

2026-01-06

downgrade

Buy

Reason

BofA lowered the firm's price target on Hutchmed to $22 from $25 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Morgan Stanley

Equal Weight -> Underweight

downgrade

$18

2025-09-22

Reason

Morgan Stanley

Price Target

$18

2025-09-22

downgrade

Equal Weight -> Underweight

Reason

Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its \"lackluster\" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HCM

Unlock Now

BofA

Buy

upgrade

$27 -> $28

2025-07-22

Reason

BofA

Price Target

$27 -> $28

2025-07-22

upgrade

Buy

Reason

BofA raised the firm's price target on Hutchmed to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.

HSBC

Buy

Hold

downgrade

$14.70

2025-05-13

Reason

HSBC

Price Target

$14.70

2025-05-13

downgrade

Buy

Hold

Reason

HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.

About HCM

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.